6-K - Telix Pharmaceuticals Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Telix Pharmaceuticals Limited appoints David Gill as Non-Executive Director effective May 11, 2026, with expectation to become Chair, and announces Company Secretary transition with Genevieve Ryan's resignation and Shomalin Naidoo's interim appointment.

Key Takeaways

1David Gill appointed Non-Executive Director effective May 11, 2026, as part of Board expansion and succession planning.

2Mr. Gill expected to succeed Dr. Mark Nelson as Chair; Nelson remains as NED.

3Genevieve Ryan resigns as Company Secretary effective April 2, 2026.

4Shomalin Naidoo appointed interim Company Secretary effective April 2, 2026, responsible for ASX communications.

5Gill brings 35+ years experience in biopharma finance, U.S. capital markets, and public company leadership.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Executive & Director Changes

David Gill

Non-Executive Director

appointed

Effective: 2026-05-11

Board expansion and succession planning

David Gill

Chair

expected appointment

Effective: in due course

succeeding Dr. Mark Nelson

Genevieve Ryan

Company Secretary

resigned

Effective: 2026-04-02

tendered resignation

Shomalin Naidoo

Company Secretary

appointed interim

Effective: 2026-04-02

interim basis while recruiting permanent

Exhibits (2)

6-K

CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS

99.1

EX-99.1